LifeTech Capital is a multi-disciplinary team of investment professionals specializing in serving the unique needs of the Biotech, MedTech and High-Tech industries and investor community. Our institutional research team provides exceptional industry insight into the complex analysis of determining the future value of drugs, devices and companies as well as access to leading key opinion leaders. With international media exposure and public appearances at both scientific and financial events, our institutional research team assists companies and investors in unlocking the value of science. LifeTech Capital’s investment banking team and capital markets team is knowledgeable in both the industry and Wall Street and develops appropriate funding strategies and structures. Our capital markets team has access to over 400 institutional investors plus a broad base of accredited retail investors through both Newbridge Securities Corporation and investor syndicates. We provide both deal and non-deal road shows in the U.S. and Europe as well as conferences and management one-on-one meetings. LifeTech Capital sets the standard for quality service and performance in the most complex and demanding of market sectors.

The LifeTech Capital Team

Stephen M. Dunn

Senior Managing Director of Healthcare

Mr. Dunn was previously the Senior Managing Director of LifeTech Capital Research at Newbridge Securities, Aurora Capital and Jesup & Lamont, as well as Director of Research for Dawson James Securities. He has also held biomedical industry management positions in Business Development, Finance and Operations having worked in over 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter (Coulter, Danaher), Cordis (Johnson & Johnson, Cardinal Health), Telectronics (St. Jude Medical, Abbott Laboratories) as well as several smaller companies. With over 30 years experience within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, M&A and joint ventures. Mr. Dunn was also a 5-star biotechnology analyst on StarMine and has made numerous appearances in both the financial and scientific media. Mr. Dunn is also a frequent speaker and panel member for many financial, medical and venture capital events.
E-mail: sdunn@lifetechcapital.com

Craig A. Pierson

Managing Director of Investment Banking

Mr. Pierson has 20 years experience in biotechnology financing as Sr. VP of investment banking at a number of firms such as Gruntal & Co., Janney Montgomery Scott, Dawson James, Jesup & Lamont and Legend Merchant. He has completed numerous transactions for both U.S. and European biotechnology companies with various structures including merchant banking, private equity, debt and private placements as well starting the European Institutional Desk at Dawson James. Mr. Pierson attended the Rochester Institute of Technology for chemical engineering and completed the executive pharmacology program at MIT. He remains active in disease-based charities such as the Joe DiMaggio Children’s Hospital, the Leukemia & Lymphoma Society, the Diabetes Research Institute and the Radiological and Imaging Alliance.
E-mail: cpierson@lifetechcapital.com

Thomas D. Masterson

Managing Director of Capital Markets

Mr. Masterson brings 25 years of capital markets experience to LifeTech Capital. Since 1990 he has held positions with bulge bracket, independent, and boutique investment firms including Paine Webber Jackson (now UBS), Shearson Lehman Brothers (now Morgan Stanley Smith Barney), Raymond James Financial Services, and most recently with I-Bankers Securities. Mr. Masterson has focused most of his career on the raising of equity and debt capital for publicly traded microcap and smallcap as well as for privately held companies. He has successfuly executed for multiple funding structures such as IPOs, Registered Directs, PIPES, ATMs, Reverse Mergers and SPACS ranging in size from $1 to $125 million. Mr. Masterson earned his BA in Finance from the University of Massachusetts, Amherst.
E-mail: tmasterson@lifetechcapital.com

Newbridge Securities Corporation

Newbridge Securities Corporation has public brokerage professionals available to assist accredited investors. See our Investor page for additional contact information. In addition, Newbridge Securities Corporation has specialized financial professionals available to assist our clients.

FINRA's BrokerCheck    Privacy Policy    Customer ID Program Notice    SEC Order Disclosure     Business Continuity Plan 

Copyright © 2009-2018 LifeTech Capital.   All Rights Reserved.
Securities offered through Newbridge Securities Corporation a member of FINRA (www.finra.org) and a member of SIPC (www.sipc.org).
SIPC provides coverage for accounts up to $500,000 (including up to $250,000 in cash) per client as defined by SIPC rules.
This coverage does not protect against the loss of the market value of securities.